MA37946B1 - Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde - Google Patents

Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde

Info

Publication number
MA37946B1
MA37946B1 MA37946A MA37946A MA37946B1 MA 37946 B1 MA37946 B1 MA 37946B1 MA 37946 A MA37946 A MA 37946A MA 37946 A MA37946 A MA 37946A MA 37946 B1 MA37946 B1 MA 37946B1
Authority
MA
Morocco
Prior art keywords
rheumatoid arthritis
treatment
csf antibody
relates
csf antibodies
Prior art date
Application number
MA37946A
Other languages
English (en)
Other versions
MA37946A1 (fr
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA37946A1 publication Critical patent/MA37946A1/fr
Publication of MA37946B1 publication Critical patent/MA37946B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps anti-gm-csf destinés à être utilisés dans le traitement de la polyarthrite rhumatoïde. L'invention concerne des anticorps anti-gm-csf, en particulier mor103, qui sont administrés à des patients souffrant de la polyarthrite rhumatoïde à des dosages qui sont avantageux dans des conditions cliniques.
MA37946A 2012-09-20 2013-09-19 Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde MA37946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
PCT/EP2013/069501 WO2014044768A1 (fr) 2012-09-20 2013-09-19 Traitement de la polyarthrite rhumatoïde

Publications (2)

Publication Number Publication Date
MA37946A1 MA37946A1 (fr) 2018-01-31
MA37946B1 true MA37946B1 (fr) 2018-09-28

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37946A MA37946B1 (fr) 2012-09-20 2013-09-19 Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde

Country Status (23)

Country Link
US (3) US20150246969A1 (fr)
EP (3) EP3345923A1 (fr)
JP (3) JP2015533806A (fr)
KR (4) KR20220028177A (fr)
CN (2) CN109999195A (fr)
AU (2) AU2013320261A1 (fr)
BR (1) BR112015006189B1 (fr)
CA (1) CA2884124A1 (fr)
CL (2) CL2015000696A1 (fr)
CR (1) CR20150153A (fr)
DO (1) DOP2015000070A (fr)
EA (1) EA031489B1 (fr)
HK (1) HK1208231A1 (fr)
IL (1) IL237554B (fr)
IN (1) IN2015KN00657A (fr)
MA (1) MA37946B1 (fr)
MX (2) MX2015003644A (fr)
MY (1) MY175388A (fr)
PE (1) PE20151079A1 (fr)
PH (1) PH12015500591A1 (fr)
SG (2) SG10201803778PA (fr)
UA (1) UA117228C2 (fr)
WO (1) WO2014044768A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療
JP6339578B2 (ja) * 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CN106659785B (zh) * 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
EA038551B1 (ru) 2015-12-17 2021-09-14 Дзе Джонс Хопкинс Юниверсити Способ лечения или профилактики системного склероза
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
CN109219616B (zh) 2016-09-19 2022-10-21 天境生物科技(杭州)有限公司 Gm-csf抗体及其用途
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (fr) 2018-09-14 2020-03-18 Universität Zürich Ligands vers gm-csf ou un récepteur gm-csf destinés à être utilisés dans une leucémie chez un patient ayant subi une allo-hct
WO2021204649A1 (fr) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Antagonistes du gm-csf destinés à être utilisés dans le traitement de la covid-19 pulmonaire sévère, du syndrome de libération de cytokine et/ou du syndrome de détresse respiratoire aiguë

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (fr) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anticorps anti-charbon, ses formulations, et procédés d'utilisation
SG176503A1 (en) * 2006-11-21 2011-12-29 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
MX2009010389A (es) * 2007-03-30 2010-01-20 Medimmune Llc Formulacion de anticuerpos.
TW200902725A (en) * 2007-04-02 2009-01-16 Genentech Inc Biological markers predictive of rheumatoid arthritis response to B-cell antagonists
AU2008235044B2 (en) 2007-04-05 2011-08-25 Sandoz Ag Stable aqueous G-CSF formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
ES2685895T3 (es) * 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
SI2376121T1 (sl) 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
WO2010128035A1 (fr) * 2009-05-05 2010-11-11 Morphosys Ag Traitement pour la sclérose en plaques
PT2341061E (pt) 2009-12-31 2013-11-05 Arven Ilac Sanayi Ve Ticaret As Um processo novo para a preparação de g-csf (fator de estimulação de colónias de granulócitos)
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
KR20140061379A (ko) 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療

Also Published As

Publication number Publication date
CL2018000933A1 (es) 2018-07-20
CN104995210A (zh) 2015-10-21
JP2022169709A (ja) 2022-11-09
HK1208231A1 (en) 2016-02-26
CR20150153A (es) 2015-09-14
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
IL237554A0 (en) 2015-04-30
EP3916013A1 (fr) 2021-12-01
PH12015500591B1 (en) 2015-05-11
UA117228C2 (uk) 2018-07-10
AU2016250388A1 (en) 2016-11-17
EA201590359A1 (ru) 2015-08-31
SG10201803778PA (en) 2018-06-28
MX2015003644A (es) 2015-09-25
JP2018138551A (ja) 2018-09-06
CN109999195A (zh) 2019-07-12
US20150246969A1 (en) 2015-09-03
BR112015006189A2 (pt) 2019-11-26
MA37946A1 (fr) 2018-01-31
DOP2015000070A (es) 2015-08-16
KR20220028177A (ko) 2022-03-08
KR20240091288A (ko) 2024-06-21
EA031489B1 (ru) 2019-01-31
CA2884124A1 (fr) 2014-03-27
AU2016250388B2 (en) 2018-07-19
BR112015006189B1 (pt) 2022-04-05
IL237554B (en) 2019-12-31
JP2015533806A (ja) 2015-11-26
PE20151079A1 (es) 2015-08-07
IN2015KN00657A (fr) 2015-07-17
MX2021006111A (es) 2021-07-07
EP2897977A1 (fr) 2015-07-29
US20210130451A1 (en) 2021-05-06
EP3345923A1 (fr) 2018-07-11
PH12015500591A1 (en) 2015-05-11
US10913792B2 (en) 2021-02-09
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (fr) 2014-03-27
CL2015000696A1 (es) 2015-10-23
AU2013320261A1 (en) 2015-04-09
KR20150056846A (ko) 2015-05-27
US20180230208A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
MA38322B1 (fr) Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA38161A1 (fr) Anticorps anti-bmp-6
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA37777B1 (fr) Préparation pharmaceutique
MA37317A1 (fr) Formulation d'anticorps il-17
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
MA48751B1 (fr) Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax